PRO 140 for Human Immunodeficiency Virus Infection

HIV Clinical Trial

Official title:

PRO 140 2103: A Phase 2a, Randomized Study of PRO 140 by Subcutaneous Injection in Adult Subjects With Human Immunodeficiency Virus Type 1 Infection

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT02257788
• Other study ID #: 1210001606
• Secondary ID: 5U01AI095085-03
• Status: Withdrawn
• Phase: Phase 2
• First received: October 2, 2014
• Last updated: March 7, 2017
• Start date: September 2014
• Est. completion date: February 2015

Study information

• Verified date: March 2017
• Source: Drexel University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

PRO 140 2103 is a multicenter, randomized parallel group study, conducted in male and female adult subjects infected with CCR5-tropic HIV-1.

Description:

Protocol PRO 140 2103 is a multicenter, randomized parallel group study, conducted in approximately 40 male and female adult subjects (n=10/treatment group) infected with CCR5-tropic HIV-1. Subjects will be randomized into one of four treatment groups. Blood samples for drug concentrations, PD variables, and efficacy variables will be obtained over a 59-day period following initiation of dosing. Safety will be monitored throughout the course of the study.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: February 2015
• Est. primary completion date: February 2015
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Males and females, age =18 years

2. Has not taken any antiretroviral therapy (ART) within 12 weeks of the early screening visit

3. Screening plasma HIV-1 RNA = 5,000 copies/mL

4. CD4+ lymphocyte cell count =500 cells/mm3 and no documented count less than or equal to 250 cells/mm3

5. Exclusive CCR5-tropic virus as determined by as determined by the Enhanced Sensitivity Trofile™ HIV Tropism Assay

6. Clinically normal resting 12-lead ECG at screening visit

7. Women of reproductive potential must have a negative serum pregnancy test at Late Screening Visit. Within hours prior to receiving the first dose of study drug, women of reproductive potential must have a negative urine pregnancy test. Male and female subjects must agree not to participate in a conception process and agree to use one barrier method of contraception plus one other highly reliable contraceptive method from the early screening visit through three weeks after the last administered subcutaneous dose of PRO 140.

Exclusion Criteria:

1. CXCR4-tropic virus, dual/mixed tropic (R5X4) virus as determined by the Enhanced Sensitivity Trofile™ HIV Tropism Assay

2. Females who are pregnant, lactating, or breastfeeding, or who plan to become pregnant during the study

3. Diagnosis of acute viral hepatitis (defined as any active infection with hepatitis A or a new diagnosis of hepatitis B or C within 24 weeks of dosing)

4. Chronic hepatitis

5. Prior use of any entry, attachment, CCR5 coreceptor, or fusion inhibitor, including PRO 140, experimental or approved

6. Any immunization or vaccination (including influenza vaccine) within 30 days prior to administration of study drug.

Related Conditions & MeSH terms

• Acquired Immunodeficiency Syndrome
• HIV
• HIV Infections
• Immunologic Deficiency Syndromes

Intervention

Biological:
• PRO 140
Humanized monoclonal antibody to CCR5

Locations

Country	Name	City	State
United States	University of Colorado Denver (Colorado ACTU)	Denver	Colorado
United States	University of Texas Health Science Center at Houston (Houston AIDS Research team (HART)	Houston	Texas
United States	Drexel University College of Medicine	Philadelphia	Pennsylvania
United States	University of Pennsylvania	Philadelphia	Pennsylvania
United States	University of Rochester Medical Center	Rochester	New York
United States	Washington University in St. Louis	St. Louis	Missouri
United States	Stanford University (Stanford AIDS Clinical Trials Unit)	Stanford	California

Sponsors (2)

Lead Sponsor	Collaborator
Drexel University	National Institute of Allergy and Infectious Diseases (NIAID)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Maximum change in viral load following initiation of different dosing regimens of PRO140	Viral Load is Defined as HIV-1 Copies/mL and Expressed as log10 Copies/mL	59 days